Regulus Therapeutics (RGLS) Earns “Neutral” Rating from Chardan Capital
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Regulus Therapeutics from a buy rating to a hold rating in a research note on Thursday. Wedbush reaffirmed an outperform rating and set a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, December 11th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an outperform rating and a $2.00 price target for the company. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $2.46.
Regulus Therapeutics (NASDAQ RGLS) traded up $0.01 during mid-day trading on Tuesday, hitting $1.40. 727,676 shares of the stock traded hands, compared to its average volume of 688,188. The company has a market capitalization of $144.50, a P/E ratio of -1.04 and a beta of 1.55. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.45. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77.
Several institutional investors and hedge funds have recently bought and sold shares of the company. NEA Management Company LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $13,737,000. FMR LLC increased its position in shares of Regulus Therapeutics by 0.5% during the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after buying an additional 37,489 shares during the period. EcoR1 Capital LLC increased its position in shares of Regulus Therapeutics by 145.6% during the second quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after buying an additional 2,199,144 shares during the period. South Dakota Investment Council increased its position in shares of Regulus Therapeutics by 37.1% during the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 492,969 shares during the period. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $750,000. Institutional investors own 59.39% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.